Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

12
231
2
14

Year Published

2020
2020
2022
2022

Publication Types

Select...
6
3

Relationship

1
8

Authors

Journals

citations
Cited by 417 publications
(259 citation statements)
references
References 30 publications
12
231
2
14
Order By: Relevance
“…The SYNTAX extended survival study, which presented a 10‐year follow‐up of 1800 patients randomly assigned to either PCI or CABG, demonstrated a lack of difference in all‐cause death between PCI and CABG. However, CABG determined a better survival benefit in patients with three‐vessel disease, but not for those with left main CAD 21 . Extrapolating these results to patients with AS and CAD, a totally percutaneous approach seems encouraging in a selected group of patients.…”
Section: Discussionmentioning
confidence: 95%
“…The SYNTAX extended survival study, which presented a 10‐year follow‐up of 1800 patients randomly assigned to either PCI or CABG, demonstrated a lack of difference in all‐cause death between PCI and CABG. However, CABG determined a better survival benefit in patients with three‐vessel disease, but not for those with left main CAD 21 . Extrapolating these results to patients with AS and CAD, a totally percutaneous approach seems encouraging in a selected group of patients.…”
Section: Discussionmentioning
confidence: 95%
“…The exclusion and inclusion criteria were based on previously described. 21,22 Briefly, the patients with following characteristics were excluded from this study, including: (1) poorly controlled blood pressure; (2) hyperlipidemia (total triglyceride > 2.26 mM); (3) diabetes (fasting glucose > 7.0 mM); (4) infectious diseases; (5) other contraindications, for example, hepatic or nephritic conditions. By the angiography analysis, patients with more than 70% stenosis were classified as experimental group (MI).…”
Section: Patients and Methods Patientsmentioning
confidence: 99%
“…4 Currently, percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG) have been widely applied to treat symptomatic patients with coronary artery disease and significantly restores the blood flow after IR injury. 5,6 However, the pathological changes of injured myocardium have not fully ameliorated since the injured microvascular architecture has not been repaired or rebuilt. Thus, exploring the mechanisms and approaches that trigger microvascular regeneration would greatly contribute to patients with coronary artery disease.…”
Section: Introductionmentioning
confidence: 99%
“…Up to 2016, we consider the PRECOMBAT and SYNTAX trials as landmarks in terms of usefulness in real life, with mid and long term follow-up prospects. Very recently, the 10-year results of the SYNTAX trial, concerning all-cause death were reported and investigators found no significant difference between PCI using DES1 (paclitaxel-eluting stents) and CABG in all-cause death, with commensurate surviving benefit in both arms, but only in patients with ULMCAD and not in those with multivessel disease (Thuijs et al, 2019).…”
Section: Randomized Clinical Trials Published Up To 2016 (Bms and Des1)mentioning
confidence: 99%